玛雅吧

中

中文 English

About Us
- Founded in 1995, Hansoh is a leading R&D-driven pharmaceutical company in China.
- Founded in 1995, Hansoh is a leading R&D-driven pharmaceutical company in China.
- Founded in 1995, Hansoh is a leading R&D-driven pharmaceutical company in China.
- Founded in 1995, Hansoh is a leading R&D-driven pharmaceutical company in China.
- Founded in 1995, Hansoh is a leading R&D-driven pharmaceutical company in China.
News
- Company News
- Media Focus
- With the objective of 'creating excellence in China's pharmaceuticals and add momentum to "Made in China"',Hansoh endeavors to make its own contribution to the “Healthy China 2030” master plan.
- With the objective of 'creating excellence in China's pharmaceuticals and add momentum to "Made in China"',Hansoh endeavors to make its own contribution to the “Healthy China 2030” master plan.
Products
- Hansoh Pharma has been committed to improving human health through continuous innovation, especially in major disease treatment fields including oncology, CNS, anti-infectives and diabetes.Constantly evolving, Hansoh makes every effort to forage itself to be a market-leading and world-renowned pharmaceutical company.
- Hansoh Pharma has been committed to improving human health through continuous innovation, especially in major disease treatment fields including oncology, CNS, anti-infectives and diabetes.Constantly evolving, Hansoh makes every effort to forage itself to be a market-leading and world-renowned pharmaceutical company.
- Hansoh Pharma has been committed to improving human health through continuous innovation, especially in major disease treatment fields including oncology, CNS, anti-infectives and diabetes.Constantly evolving, Hansoh makes every effort to forage itself to be a market-leading and world-renowned pharmaceutical company.
- Hansoh Pharma has been committed to improving human health through continuous innovation, especially in major disease treatment fields including oncology, CNS, anti-infectives and diabetes.Constantly evolving, Hansoh makes every effort to forage itself to be a market-leading and world-renowned pharmaceutical company.
- Hansoh Pharma has been committed to improving human health through continuous innovation, especially in major disease treatment fields including oncology, CNS, anti-infectives and diabetes.Constantly evolving, Hansoh makes every effort to forage itself to be a market-leading and world-renowned pharmaceutical company.
- Hansoh Pharma has been committed to improving human health through continuous innovation, especially in major disease treatment fields including oncology, CNS, anti-infectives and diabetes.Constantly evolving, Hansoh makes every effort to forage itself to be a market-leading and world-renowned pharmaceutical company.
R&D
- Hansoh has been holding on to the strategy of technology and innovation, and established R&D centers located in Lianyungang and Shanghai.
- Hansoh has been holding on to the strategy of technology and innovation, and established R&D centers located in Lianyungang and Shanghai.
- Hansoh has been holding on to the strategy of technology and innovation, and established R&D centers located in Lianyungang and Shanghai.
- Hansoh has been holding on to the strategy of technology and innovation, and established R&D centers located in Lianyungang and Shanghai.
Services
- Hansoh pursuits the philosophy of “Professional marketing of medical products for benefits of all doctors and patients” to actively carry out national policies and establish innovate marketing systems
- Hansoh pursuits the philosophy of “Professional marketing of medical products for benefits of all doctors and patients” to actively carry out national policies and establish innovate marketing systems
- Hansoh pursuits the philosophy of “Professional marketing of medical products for benefits of all doctors and patients” to actively carry out national policies and establish innovate
Contact Us
- Hansoh sticks to providing “attractive career opportunities, cohesive corporate culture, continuous learning and incentive mechanism” so that employees can have clear career path for both administrative ranks and technical titles.
- Hansoh sticks to providing “attractive career opportunities, cohesive corporate culture, continuous learning and incentive mechanism” so that employees can have clear career path for both administrative ranks and technical titles.
- Hansoh sticks to providing “attractive career opportunities, cohesive corporate culture, continuous learning and incentive mechanism” so that employees can have clear career path for both administrative ranks and technical titles.
- Hansoh sticks to providing “attractive career opportunities, cohesive corporate culture, continuous learning and incentive mechanism” so that employees can have clear career path for both administrative ranks and technical titles.



Fulaixin (Empagliflozin Tablets)

Empagliflozin Tablets

English Name: Empagliflozin Tablets

Chinese Pinyin: Engeliejing Pian

The active ingredient of this product is empagliflozin.

Chemical Name: (1S)-1, 5-anhydrous-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furyl]oxy]phenyl]methyl]phenyl]-D-glucitol.

/en/upload/images/2021/06/17/0b2507b285014f4f8bb9c28633b36613.png

【Name】	Common Name: Empagliflozin Tablets English Name: Empagliflozin Tablets Chinese Pinyin: Engeliejing Pian
【Ingredients】	Active Ingredient: empagliflozin Chemical Name: (1S)-1, 5-anhydrous-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furyl]oxy]phenyl]methyl]phenyl]-D-glucitol. Structural Formula: Molecular Formula: C₂₃H₂₇ClO₇ Molecular Weight: 450.9
【Description】	This product is a film-coated tablet, appearing white or off-white after removing the coating.
【Indication】	This product is indicated for the treatment of type 2 diabetes.
【Strength】	(1) 10mg; (2) 25mg.
【Dosage and Administration】	Recommended Dose The recommended dose of this product is 10mg in the morning, once a day, on an empty stomach or after eating. In patients who tolerate this product, the dose can be increased to 25mg. In patients with hypovolemia, correction of hypovolemia is recommended prior to initiation of this product (see 【Precautions】). Patients with Renal Damage Assessment of renal function is recommended prior to initiation of this product and should be done periodically thereafter. This product should not be used in patients with eGFR below 45mL/min/1.73m2. Dose adjustment is not required for patients with eGFR greater than or equal to 45mL/min/1.73m2. This product should be discontinued if eGFR is consistently below 45mL/min/1.73m2 (see 【Precautions】). Patients with Liver Damage Dose adjustment is not required for patients with liver damage. Patients with severe liver damage have increased exposure to empagliflozin. Experience with treatment in patients with severe liver damage is limited, so it is not recommended for this population. Note: Please refer to the Product Manual for details.